How would you approach maintenance therapy following chemo-immunotherapy for extensive-stage small cell lung cancer per the IMPower133 trial if there is a mixed response post-treatment but clearly some clinical benefit?
Would you proceed with maintenance atezolizumab or switch to second line therapy?
Community PollStarted
How would you approach maintenance therapy following chemo-immunotherapy for extensive-stage SCLC if there is a mixed radiographic response post-treatment?
73 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University Hospitals Seidman Cancer Center and Case Western Reserve University
Answered on
The definition of clinical benefit remains a very subjective one. We presume that the patient has had an overall good response to the combination of chemotherapy and immunotherapy, and has undergone restaging imaging during the immunotherapy alone maintenance stage. The above question would suggest ...
Join for free or sign in to see the full answer